Valérie Journot

Summary

Country: France

Publications

  1. ncbi request reprint Viral load as a primary outcome in human immunodeficiency virus trials: a review of statistical analysis methods
    V Journot
    INSERM U330, 146 rue Leo Saignat, 33076 Bordeaux Cedex, France
    Control Clin Trials 22:639-58. 2001
  2. ncbi request reprint Use of efavirenz is not associated with a higher risk of depressive disorders: a substudy of the randomized clinical trial ALIZE-ANRS 099
    Valérie Journot
    INSERM, U593, Bordeaux, France
    Clin Infect Dis 42:1790-9. 2006
  3. ncbi request reprint About the necessity to manage events coded with MedDRA prior to statistical analysis: proposal of a strategy with application to a randomized clinical trial, ANRS 099 ALIZE
    Valérie Journot
    INSERM, U593, F 33076 Bordeaux, France
    Contemp Clin Trials 29:95-101. 2008
  4. doi request reprint Preserving participant anonymity during remote preenrollment consent form checking
    Valérie Journot
    INSERM, CIC EC7, Bordeaux, France
    Clin Trials 10:460-2. 2013
  5. ncbi request reprint Analysis of undetectable HIV RNA using survival analysis: results must be interpreted carefully
    Rodolphe Thiebaut
    INSERM U593, Institut de Santé Publique d Epidémiologie et de Développement, Bordeaux, France
    HIV Clin Trials 4:417-20. 2003
  6. ncbi request reprint Changes in the peripheral blood mtDNA levels in naive patients treated by different nucleoside reverse transcriptase inhibitor combinations and their association with subsequent lipodystrophy
    Genevieve Chene
    INSERM, U593, F 33076 Bordeaux, France
    AIDS Res Hum Retroviruses 23:54-61. 2007
  7. doi request reprint Validation of a risk-assessment scale and a risk-adapted monitoring plan for academic clinical research studies--the Pre-Optimon study
    Valérie Journot
    INSERM, U897, F 33076 Bordeaux, France
    Contemp Clin Trials 32:16-24. 2011
  8. doi request reprint Remote preenrollment checking of consent forms to reduce nonconformity
    Valérie Journot
    INSERM, CIC EC7, Bordeaux, France
    Clin Trials 10:449-59. 2013
  9. ncbi request reprint Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients
    Genevieve Chene
    INSERM Unité 330, Universite Victor Segalen Bordeaux 2, 33076 Bordeaux Cedex, France
    Clin Infect Dis 34:649-57. 2002

Detail Information

Publications9

  1. ncbi request reprint Viral load as a primary outcome in human immunodeficiency virus trials: a review of statistical analysis methods
    V Journot
    INSERM U330, 146 rue Leo Saignat, 33076 Bordeaux Cedex, France
    Control Clin Trials 22:639-58. 2001
    ....
  2. ncbi request reprint Use of efavirenz is not associated with a higher risk of depressive disorders: a substudy of the randomized clinical trial ALIZE-ANRS 099
    Valérie Journot
    INSERM, U593, Bordeaux, France
    Clin Infect Dis 42:1790-9. 2006
    ..Whether the use of EFV is associated with the risk of depression or suicide remains controversial...
  3. ncbi request reprint About the necessity to manage events coded with MedDRA prior to statistical analysis: proposal of a strategy with application to a randomized clinical trial, ANRS 099 ALIZE
    Valérie Journot
    INSERM, U593, F 33076 Bordeaux, France
    Contemp Clin Trials 29:95-101. 2008
    ....
  4. doi request reprint Preserving participant anonymity during remote preenrollment consent form checking
    Valérie Journot
    INSERM, CIC EC7, Bordeaux, France
    Clin Trials 10:460-2. 2013
    ..This procedure requires a copy of the consent form that partially masks the fields for participant's name and signature; this copy is faxed to the clinical trials unit for checking...
  5. ncbi request reprint Analysis of undetectable HIV RNA using survival analysis: results must be interpreted carefully
    Rodolphe Thiebaut
    INSERM U593, Institut de Santé Publique d Epidémiologie et de Développement, Bordeaux, France
    HIV Clin Trials 4:417-20. 2003
    ..The potential for loss of information might yield differential misclassification biases and therefore unreliable results. Longitudinal models are better suited to analyze the repeated measures of a continuous outcome such as HIV RNA...
  6. ncbi request reprint Changes in the peripheral blood mtDNA levels in naive patients treated by different nucleoside reverse transcriptase inhibitor combinations and their association with subsequent lipodystrophy
    Genevieve Chene
    INSERM, U593, F 33076 Bordeaux, France
    AIDS Res Hum Retroviruses 23:54-61. 2007
    ..Furthermore, a low mtDNA level at month 12 was associated with the subsequent development of lipodystrophy. This marker may be of value for the early prevention of lipodystrophy in treated HIV-infected patients...
  7. doi request reprint Validation of a risk-assessment scale and a risk-adapted monitoring plan for academic clinical research studies--the Pre-Optimon study
    Valérie Journot
    INSERM, U897, F 33076 Bordeaux, France
    Contemp Clin Trials 32:16-24. 2011
    ..Standardization is needed, and relies on definition and validation of tools accounting for risk...
  8. doi request reprint Remote preenrollment checking of consent forms to reduce nonconformity
    Valérie Journot
    INSERM, CIC EC7, Bordeaux, France
    Clin Trials 10:449-59. 2013
    ..In biomedical research, the signed consent form must be checked for compliance with regulatory requirements. Checking usually is performed on site, most frequently after a participant's final enrollment...
  9. ncbi request reprint Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients
    Genevieve Chene
    INSERM Unité 330, Universite Victor Segalen Bordeaux 2, 33076 Bordeaux Cedex, France
    Clin Infect Dis 34:649-57. 2002
    ..4; P=.007). No difference was observed in cholesterol and glucose levels as a function of any pattern of antiretroviral exposure. Exposure to stavudine and didanosine was associated with LD syndrome (predominantly lipoatrophy)...